Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort

Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis. We aimed to evaluate the short-term microbiological efficacy and the tolerability profile of bedaquiline. We performed a retrospective cohort study among patients with MDR tuberculosis rece...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical infectious diseases Ročník 60; číslo 2; s. 188
Hlavní autoři:	Guglielmetti, Lorenzo, Le Dû, Damien, Jachym, Mathilde, Henry, Benoît, Martin, Diane, Caumes, Eric, Veziris, Nicolas, Métivier, Nathalie, Robert, Jérôme
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 15.01.2015
Témata:	Adolescent Adult Aged Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Cohort Studies Compassionate Use Trials Diarylquinolines - adverse effects Diarylquinolines - therapeutic use Drug-Related Side Effects and Adverse Reactions Extensively Drug-Resistant Tuberculosis - drug therapy Female France Humans Male Middle Aged Mycobacterium tuberculosis - isolation & purification Retrospective Studies Treatment Outcome Young Adult France multidrug-resistant tuberculosis TMC207 bedaquiline extensively drug-resistant tuberculosis safety
ISSN:	1537-6591, 1537-6591
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!